K. Imrie

发表

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis

V. Kukreti, M. Crump, J. Kuruvilla, 2014, Leukemia & lymphoma.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†

Bingshu E. Chen, K. Savage, T. Reiman, 2018, Leukemia & lymphoma.

CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature

E. Franssen, R. Buckstein, W. Lim, 2003, Leukemia & lymphoma.

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

R. Buckstein, M. Cheung, N. Berinstein, 2013 .

Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: Treatment effect according to baseline prognostic factors

R. Marcus, A. Belch, P. Solal-Céligny, 2005 .

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.

R. Marcus, D. Cunningham, A. Belch, 2005 .

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2005, Blood.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

R. Marcus, A. Dmoszyńska, P. Solal-Céligny, 2006 .

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2003 .

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Bingshu E. Chen, M. Federico, V. Kukreti, 2012 .

Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months.

K. Alberti, J. Mathers, N. Unwin, 2001, Diabetes research and clinical practice.

Bortezomib in Multiple Myeloma and Lymphoma

D. Reece, K. Imrie, T. Kouroukis, 2012 .

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.

A. Prica, K. Imrie, M. Cheung, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

R. Marcus, D. Cunningham, A. Belch, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In situ localization of follicular lymphoma: evidence for subclinical systemic disease with detection of an identical BCL-2/IGH fusion gene in blood and lymph node

K. Imrie, M. Cheung, K. Imrie, 2009, Leukemia.

Bortezomib in multiple myeloma: systematic review and clinical considerations.

D. Reece, K. Imrie, M. Cheung, 2014, Current oncology.